Current fertility research
Below you can read in a bit more detail about our current projects. Should you be interested in participating in any of our projects, or perhaps joining our Patient Research Advisory Board, which helps us focus on answering questions important to you, please contact us.
This research study aims to look at whether pregnancy rates are improved after IVF in poor responders when given dehydroepiandrosterone (DHEA), a naturally occurring hormone that is thought to increase the number of eggs produced by these women when given before and during their IVF treatment. It will also look at the number of eggs they produce, the quality of their embryos as well as how many of their pregnancies result in a live birth or miscarriage.
One factor that determines the success of IVF is how many eggs are produced, as this will affect how many embryos are created. Some women tend either not to respond to the drugs that cause egg production during IVF or produce very few eggs and are termed poor responders.
Women who meet an internationally agreed consensus definition of poor responders who are having IVF at our centre and agree to take part in the study can participate. The women will have any two of the following:
1. Advanced maternal age (≥40 years) or any other risk factor for poor ovarian response (POR)
2. Previous poor ovarian response
3. An abnormal ovarian reserve test
Two groups of poor responders going through IVF (200 in each group) will be studied. One group will be given 75 mg DHEA daily and the other a placebo (dummy tablet) to take for 10 weeks before their IVF. Patients will be assigned to the groups at random and neither they nor the researchers will know which medication they are taking. There will be no change to their IVF treatment. We will follow their treatment and compare the number of women in each group who get pregnant.
The main benefit of the study is to provide a definitive answer whether DHEA make a difference in IVF outcome in this group of women. If the claims about the effects of DHEA are true, then those in the group taking it, and in the broader context many poor responder women, will benefit by getting pregnant. If the claims are not proven then again many poor responder women will be spared the financial and emotional cost of using an ineffective drug. As far as we can tell from our reading, DHEA is safe at the dose and duration that we will be using it. Several women have used it with no reported significant risk.
For more information on this study please contact Sue Wellstead or Teresa Gubbins on 023 8120 6856 or firstname.lastname@example.org / email@example.com.